Cystatin C levels in patients with β-thalassemia during deferasirox treatment

Blood Cells, Molecules, and Diseases

Volumn 44, Issue 3, 2010, Pages 152-155

  Papassotiriou, Ioannis ^a   Margeli, Alexandra ^a   Hantzi, Eugenia ^a   Delaporta, Polyxeni ^b   Sergounioti, Athanassia ^a   Goussetis, Evgenios ^a   Ladis, Vassilios ^b   Kattamis, Antonis ^b  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chelation; Renal injury; Thalassemia

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; DEFERASIROX; FERRITIN; IRON; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHEMOLUMINESCENCE; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMIC PARAMETERS; HUMAN; IRON KINETICS; IRON OVERLOAD; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; NEPHELOMETRY; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IRON CHELATING AGENTS; LIPOCALINS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; TRIAZOLES; YOUNG ADULT;

EID: 76849113241     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.01.001     Document Type: Article

References (21)

1. Roos J.F., Doust J., Tett S.E., and Kirkpatrick C.M. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clin. Biochem. 40 (2007) 383-391
2. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 107 (2006) 3455-3462
3. Galanello R., Piga A., Forni G.L., Bertrand Y., Foschini M.L., Bordone E., et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica 91 (2006) 1343-1351
4. ®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91 (2006) 873-880
5. Porter J., Galanello R., Saglio G., Neufeld E.J., Vichinsky E., Cappellini M.D., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol. 80 (2008) 168-176
6. Galanello R., Piga A., Alberti D., Rouan M.C., Bigler H., and Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J. Clin. Pharmacol. 43 (2003) 565-572
7. Vichinsky E., Onyekwere O., Porter J., Swerdlow P., Eckman J., Lane P., et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br. J. Haematol. 136 (2007) 501-508
8. ®) with up to 4.5 years of treatment in patients with thalassemia major: a pooled analysis. Blood 112 11 (2008) abst 5411
9. Vichinsky E. Clinical application of deferasirox: practical patient management. Am. J. Hematol. 83 (2008) 398-402
10. Gattermann N., Zoumbos N., Angelucci E., Drelichman G., Siegel J., Glimm E., et al. Impact on iron removal of dose reduction for non-progressive serum creatinine increases during treatment with the once-daily, oral iron chelator deferasirox (Exjade, ICL670). Blood 108 (2006) 32b, abst 3824
11. Exjade (deferasirox) Prescribing Information. Novartis Pharmaceuticals Corporation.2007. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf.
12. Stevens L.A., Coresh J., Schmid C.H., Feldman H.I., Froissart M., Kusek J., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 51 (2008) 395-406
13. Bolignano D., Lacquaniti A., Coppolino G., Donato V., Campo S., Fazio M., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4 (2009) 337-344
14. Kattamis A., Margeli A., Hantzi E., Paleologos G., Sergounioti A., Lourida A., et al. Assessment of renal function in transfused beta-thalassemia patients based on cystatin C measurements and equations. Blood 110 (2007) (11):abst 2796
15. Kuwabara T., Mori K., Mukoyama M., Kasahara M., Ykoi H., Saito Y., Yoshioka T., et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 75 (2009) 285-294
16. Curhan G. Cystatin C: a marker of renal function or something more. Clin. Chem. 51 (2005) 293-294
17. Johnston N., Jernberg T., Lindahl B., Lindback J., Stridsberg M., Larsson A., et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin. Biochem. 37 (2004) 210-216
18. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., de Z.D., Curhan G.C., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65 (2004) 1416-1421
19. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin. Chem. 51 (2005) 321-327
20. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351 (2004) 1296-1305
21. Voskaridou E., Plata E., Christoulas D., Xirakia C., Stoupa E., Varvagiannis K., et al. Deferasirox reduces serum TNF-a but impairs renal function in patients with thalassemia major after 12 months of therapy. Blood 112 (2008) (11) abst 3888